Trends in On-label and Off-label Modafinil Use in a Nationally Representative Sample

search, Department of Medicine, Baylor College of Medicine, Houston (Drs Singh, Petersen, and Sawhney); Department of Psychology, University of Houston, Houston (Dr Spitzmueller); and School of Biomedical Informatics and University of Texas–Memorial Hermann Center for Healthcare Quality and Safety, University of Texas Health Science Center at Houston (Dr Sittig). Correspondence: Dr Singh, Michael E. DeBakey Veterans Affairs Medical Center (152), 2002 Holcombe Blvd, Houston, TX 77030 (hardeeps@bcm.edu). Author Contributions: Dr Singh had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Singh, Spitzmueller, Sawhney, and Sittig. Acquisition of data: Singh and Spitzmueller. Analysis and interpretation of data: Singh, Spitzmueller, Petersen, Sawhney, and Sittig. Drafting of the manuscript: Singh, Spitzmueller, and Sittig. Critical revision of the manuscript for important intellectual content: Singh, Spitzmueller, Petersen, Sawhney, and Sittig. Statistical analysis: Spitzmueller and Petersen. Obtained funding: Singh. Administrative, technical, and material support: Singh and Sittig. Study supervision: Singh and Sittig. Conflict of Interest Disclosures: None reported. Funding/Support: The research reported herein was supported by the Department of Veterans Affairs National Center for Patient Safety, a National Institutes of Health K23 career development award (K23CA125585) to Dr Singh and in part by the Houston VA Health Services Research and Development Center of Excellence (HFP90020). Dr Sittig is supported in part by a SHARP contract from the Office of the National Coordinator for Health Information Technology (ONC No. 10510592). Additional Contributions: We thank additional members of our project team, Donna Espadas, BS; Daniel Murphy, MD, MBA; Michael Smith, PhD; and Archana Laxmisan,MD,MA(allaffiliatedwiththeHoustonVAHealth ServicesResearchandDevelopmentCenterofExcellence), for theirvaluablecontributions to thesurvey.Noneof them received additional compensation for this work. Disclaimer: The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or any other funding agencies.

[1]  Dean F Sittig,et al.  Notifications received by primary care practitioners in electronic health records: a taxonomy and time analysis. , 2012, The American journal of medicine.

[2]  Simran Singh,et al.  Understanding the management of electronic test result notifications in the outpatient setting , 2011, BMC Medical Informatics Decis. Mak..

[3]  David M. Studdert,et al.  Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints , 2011, PLoS Medicine.

[4]  Assessment report for modafinil containing medicinal products , 2011 .

[5]  Dean F Sittig,et al.  A new sociotechnical model for studying health information technology in complex adaptive healthcare systems , 2010, Quality and Safety in Health Care.

[6]  Dean F. Sittig,et al.  Ten Strategies to Improve Management of Abnormal Test Result Alerts in the Electronic Health Record , 2010, Journal of patient safety.

[7]  Hardeep Singh,et al.  Eight recommendations for policies for communicating abnormal test results. , 2010, Joint Commission journal on quality and patient safety.

[8]  Dean F Sittig,et al.  Notification of abnormal lab test results in an electronic medical record: do any safety concerns remain? , 2010, The American journal of medicine.

[9]  Dean F. Sittig,et al.  Timely follow-up of abnormal diagnostic imaging test results in an outpatient setting: are electronic medical records achieving their potential? , 2009, Archives of internal medicine.

[10]  J. Ballon,et al.  A systematic review of modafinil: Potential clinical uses and mechanisms of action. , 2006, The Journal of clinical psychiatry.

[11]  D. Dinges,et al.  Modafinil for excessive sleepiness associated with shift-work sleep disorder. , 2005, The New England journal of medicine.

[12]  A. Pack,et al.  Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. , 2001, American journal of respiratory and critical care medicine.

[13]  N J Douglas,et al.  Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. , 2001, American journal of respiratory and critical care medicine.

[14]  D. Fry,et al.  Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy , 1998, Annals of neurology.